BeOne Medicines Ltd.

ONC· Nasdaq, OTC· Pharmaceutical Preparations

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
17.6%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
+76.8%
We record prices for the companies we cover; ONC is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
1.47B
Revenue
$5.3B
Free cash flow
$941.7M
Owner earnings
$430.9M

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
87.5%
Operating
8.4%
Net
5.4%
Free cash flow
17.6%
Owner earnings
8.1%
Stock pay
9.6%

Returns

ROIC, FY2025
36.6%
ROIC, 5 yr avg
–
ROE, FY2025
6.6%
ROE, 5 yr avg
-21.4%

Growth (CAGR)

Revenue, 3 yr
55.7%
Revenue, 5 yr
76.8%
Revenue, 9 yr
157.6%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Diluted EPS, 9 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–
Free cash flow, 9 yr
–

Financial health · FY2025

Cash and investments
$4.5B
Total debt
$1.0B
Net cash
$3.5B
Debt/Equity
0.2x
Debt/FCF
1.1x

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
6.3%

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$5.3B

+157.6% a year over 9 years

FY2016: Revenue $1.1MFY2017: Revenue $238.4MFY2018: Revenue $198.2MFY2019: Revenue $428.2MFY2020: Revenue $308.9MFY2021: Revenue $1.2BFY2022: Revenue $1.4BFY2023: Revenue $2.5BFY2024: Revenue $3.8BFY2025: Revenue $5.3B
FY2016FY2025

Margins

Gross87.5%Operating8.4%Net5.4%

FY2025

FY2016: Gross –, Operating -10940.2%, Net -11141.8%FY2017: Gross –, Operating -41.3%, Net -39.1%FY2018: Gross –, Operating -356.1%, Net -339.9%FY2019: Gross –, Operating -224.2%, Net -221.5%FY2020: Gross –, Operating -536.7%, Net -526.1%FY2021: Gross 86.0%, Operating -122.3%, Net -123.9%FY2022: Gross 79.8%, Operating -126.4%, Net -141.5%FY2023: Gross 84.5%, Operating -49.1%, Net -35.9%FY2024: Gross 84.4%, Operating -14.9%, Net -16.9%FY2025: Gross 87.5%, Operating 8.4%, Net 5.4%
FY2016FY2025

Free cash flow and owner earnings

Free cash flow$941.7MOwner earnings$430.9M

FY2025

FY2016: Free cash flow -$113.0M, Owner earnings -$123.6MFY2017: Free cash flow -$33.6M, Owner earnings -$76.5MFY2018: Free cash flow -$618.0M, Owner earnings -$705.1MFY2019: Free cash flow -$839.9M, Owner earnings -$974.0MFY2020: Free cash flow -$1.4B, Owner earnings -$1.6BFY2021: Free cash flow -$1.6B, Owner earnings -$1.8BFY2022: Free cash flow -$1.8B, Owner earnings -$2.1BFY2023: Free cash flow -$1.7B, Owner earnings -$2.1BFY2024: Free cash flow -$633.3M, Owner earnings -$1.1BFY2025: Free cash flow $941.7M, Owner earnings $430.9M
FY2016FY2025

Diluted shares

1.47B

+88.9% over 9 years, net dilution

FY2016: Diluted shares –FY2017: Diluted shares –FY2018: Diluted shares –FY2019: Diluted shares 780.7MFY2020: Diluted shares 1.09BFY2021: Diluted shares 1.21BFY2022: Diluted shares 1.34BFY2023: Diluted shares 1.36BFY2024: Diluted shares 1.37BFY2025: Diluted shares 1.47B
FY2016FY2025

Return on invested capital

36.6%

FY2025

FY2016: ROIC –FY2017: ROIC –FY2018: ROIC –FY2019: ROIC –FY2020: ROIC –FY2021: ROIC –FY2022: ROIC –FY2023: ROIC –FY2024: ROIC –FY2025: ROIC 36.6%
FY2016FY2025

Net cash

$3.5B

$3.5B more cash than debt

FY2016: Net cash $350.9MFY2017: Net cash $819.1MFY2018: Net cash $1.7BFY2019: Net cash $899.4MFY2020: Net cash $3.8BFY2021: Net cash $6.0BFY2022: Net cash $4.0BFY2023: Net cash $2.3BFY2024: Net cash $1.6BFY2025: Net cash $3.5B
FY2016FY2025

Every figure, year by year

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
The business
Revenue$1.1M$238.4M$198.2M$428.2M$308.9M$1.2B$1.4B$2.5B$3.8B$5.3B
Revenue growth-87.9%22179.2%-16.8%116.0%-27.9%280.8%20.4%73.7%55.0%40.2%
Gross margin–––––86.0%79.8%84.5%84.4%87.5%
Operating margin-10940.2%-41.3%-356.1%-224.2%-536.7%-122.3%-126.4%-49.1%-14.9%8.4%
Net income-$119.2M-$93.1M-$673.8M-$948.6M-$1.6B-$1.5B-$2.0B-$881.7M-$644.8M$286.9M
Net margin-11141.8%-39.1%-339.9%-221.5%-526.1%-123.9%-141.5%-35.9%-16.9%5.4%
Diluted EPS–––$-1.22$-1.50$-1.21$-1.49$-0.65$-0.47$0.19
Return on invested capital?–––––––––36.6%
Cash
Operating cash flow-$89.5M$12.8M-$547.7M-$750.3M-$1.3B-$1.3B-$1.5B-$1.2B-$140.6M$1.1B
Capital expenditure$23.5M$46.4M$70.3M$89.6M$117.5M$262.9M$325.4M$561.9M$492.7M$185.8M
Free cash flow-$113.0M-$33.6M-$618.0M-$839.9M-$1.4B-$1.6B-$1.8B-$1.7B-$633.3M$941.7M
Stock-based compensation$10.6M$42.9M$87.1M$134.2M$183.5M$240.7M$303.2M$367.6M$441.6M$510.9M
Owner earnings?-$123.6M-$76.5M-$705.1M-$974.0M-$1.6B-$1.8B-$2.1B-$2.1B-$1.1B$430.9M
Free cash flow per share–––$-1.08$-1.29$-1.29$-1.36$-1.27$-0.46$0.64
Capital allocation
Dividends paid––––––––––
Share repurchases––––––––––
Diluted shares–––780.7M1.09B1.21B1.34B1.36B1.37B1.47B
Share count change?––––39.0%11.2%11.2%1.2%0.9%7.8%
Balance sheet
Cash and equivalents$87.5M$239.6M$712.9M$618.0M$1.4B$4.4B$3.9B$3.2B$2.6B$4.5B
Short-term investments$280.7M$597.9M$1.1B$364.7M$3.3B$2.2B$665.3M$2.6M––
Total debt$17.3M$18.4M$49.5M$83.3M$853.7M$629.7M$538.1M$886.0M$1.0B$1.0B
Net debt-$350.9M-$819.1M-$1.7B-$899.4M-$3.8B-$6.0B-$4.0B-$2.3B-$1.6B-$3.5B
Shareholders' equity$352.9M$669.8M$1.7B$962.2M$3.9B$6.1B$4.4B$3.5B$3.3B$4.4B

Latest filings

All on EDGAR
2026-08-268-KEarnings release
2026-08-0510-QQuarterly report
2026-08-058-KEarnings release
2026-05-0610-QQuarterly report
2026-05-068-KEarnings release
2026-04-28DEF 14AProxy statement
2026-04-148-KEarnings release
2026-02-2610-KAnnual report
2026-02-268-KEarnings release
2025-11-0610-QQuarterly report

More from our coverage

All coverage